ESMO 2024 - Small Cell Lung Cancer

BEAT-SC Trial: Phase 3 Study of Bevacizumab or Placebo With Atezolizumab and Platinum-Based Chemotherapy in ES-SCLC

The second interim analysis of overall survival from the BEAT-SC trial assessed bevacizumab for its effectiveness and safety in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) in Japan and China. Read More ›

Real-World Outcomes of Relapsed and Refractory Systemic Therapy in the Canadian SCLC Database (CASCADE)

ESMO 2024 - Small Cell Lung Cancer

This study evaluated real-world treatments and outcomes of limited disease small cell lung cancer (SCLC) using the Canadian SCLC Database (CASCADE). Read More ›

An Open-Label, Multicenter Phase 2 Trial Assessed Encorafenib Plus Binimetinib in Patients With Previously Untreated BRAF V600E-Mutant Advanced NSCLC

ESMO 2024 - Small Cell Lung Cancer

An ongoing, open-label, single-arm phase 2 study (IFCT-1904) evaluated patients with untreated BRAF V600E-mutant non-small cell lung cancer (NSCLC) who received encorafenib plus binimetinib. Read More ›

Results of a Phase 2 Study Evaluating Lurbinectedin and Irinotecan in Relapsed SCLC Patients With Chemotherapy-Free Interval >30 Days

ESMO 2024 - Small Cell Lung Cancer

Data from phase 2 trials involving lurbinectedin and irinotecan have been analyzed for patients with relapsed small cell lung cancer (SCLC) who have had a chemotherapy-free interval of >30 days. Read More ›

Analysis of 5-Year Outcomes From the NEOSTAR and CA209-159 Studies on Neoadjuvant Nivolumab and the Combination of Nivolumab With Ipilimumab in Resectable NSCLC

ESMO 2024 - Small Cell Lung Cancer

A pooled analysis of 5-year clinical outcomes from 2 early-phase trials, NEOSTAR and CA209-159, showed promising long-term clinical effectiveness in patients with resectable non-small cell lung cancer (NSCLC). Read More ›